Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.71 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

9 Analysts Have This to Say About Genmab ↗

November 28, 2023

Via Benzinga

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

November 27, 2023

From Genmab A/S

Via Business Wire

7 Must-Buy Stocks That Are on Ridiculous Discount Now ↗

November 13, 2023

With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale.

Via InvestorPlace

NASDAQ:GMAB is not too expensive for the growth it is showing. ↗

November 10, 2023

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.

Via Chartmill

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Analyst Expectations for Genmab's Future ↗

November 08, 2023

Via Benzinga

NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗

November 01, 2023

GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

November 02, 2023

From Genmab A/S

Via Business Wire

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023

From Seagen Inc.

Via Business Wire

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

October 20, 2023

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

What 13 Analyst Ratings Have To Say About Genmab ↗

October 13, 2023

Via Benzinga

Expert Ratings for Genmab ↗

September 26, 2023

Via Benzinga

Analyst Expectations for Genmab's Future ↗

September 05, 2023

Via Benzinga

United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 18, 2023

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher ↗

September 26, 2023

With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.

Via InvestorPlace

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

September 25, 2023

From Genmab A/S

Via Business Wire

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

September 25, 2023

From Genmab A/S

Via Business Wire

Analyst Expectations for Genmab's Future ↗

August 15, 2023

Via Benzinga

12 Analysts Have This to Say About Genmab ↗

July 24, 2023

Via Benzinga

Why Shares of Iovance Biotherapeutics Dropped Thursday ↗

September 14, 2023

The biotech stock's lead therapy is looking at some competition.

Via The Motley Fool

AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗

September 11, 2023

On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients

Via Benzinga

Why Shares of Zai Lab Limited Were Jumping on Tuesday ↗

September 05, 2023

Zai Lab's shares benefited from positive clinical trial news.

Via The Motley Fool

Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications ↗

September 05, 2023

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on...

Via Benzinga

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

September 04, 2023

From Seagen Inc.

Via Business Wire

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

September 04, 2023

From Genmab A/S

Via Business Wire

The 3 Most Promising Biotech Stocks to Own Now ↗

August 31, 2023

These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023 ↗

August 24, 2023

Via Benzinga

Is AbbVie Still a Good Dividend Stock to Buy? ↗

August 08, 2023

Find out if AbbVie can overcome sinking sales of its top-selling product.

Via The Motley Fool

3 Things About Johnson & Johnson Every Smart Investor Knows ↗

July 28, 2023

The company has been a strong value stock but faces big changes this year.

Via The Motley Fool

3 Biotech Stocks You Better Be Buying on Each and Every Dip ↗

July 27, 2023

Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.

Via InvestorPlace

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Starting at $3.75/week.

Subscribe Today